Interleukin 6 enhances glycolysis through expression of the glycolytic enzymes hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3

Journal of Nippon Medical School

Volumn 77, Issue 2, 2010, Pages 97-105

  Ando, Masaru ^a   Uehara, Lkuno ^a   Kogure, Kayo ^a   Asano, Yumi ^a   Nakajima, Wataru ^a   Abe, Yoshinori ^a   Kawauchi, Keiko ^a   Tanaka, Nobuyuki ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

6 phosphofructo 2 kinase fructose 2,6 bisphosphatase 3; Glycolysis; Hexokinase 2; Interleukin 6; STAT3

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; FRUCTOSE 2,6 BISPHOSPHATASE; HEXOKINASE; HEXOKINASE 2; INTERLEUKIN 6; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INDUCTION; GLYCOLYSIS; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

ANIMALS; FIBROBLASTS; GLUCOSE; GLYCOLYSIS; HEP G2 CELLS; HEXOKINASE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LACTIC ACID; LIVER NEOPLASMS; MICE; PHOSPHOFRUCTOKINASE-2; RECOMBINANT PROTEINS; RNA INTERFERENCE; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 77950945700     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.77.97     Document Type: Article

References (27)

1. Warburg O: On respiratory impairment in cancer cells. Science 1956; 124: 269-270.
2. Kim JW, Dang CV: Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66: 8927-8930.
3. Gatenby RA, Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891-899.
4. Hsu PP, Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell 2008; 134: 703-707.
5. Kawauchi K. Araki K. Tobiume K. Tanaka N; p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation. Nat Cell Biol 2008; 10: 611-618. (Pubitemid 351627381)
6. Karin M: Nuclear factor-κB in cancer development and progression. Nature 2006; 441: 431-436.
7. Li Q, Verma IM: NF-κB regulation in the immune system. Nat Rev Immunol 2002; 2: 725-734.
8. Vallabhapurapu S, Karin M: Regulation and function of NF-κB transcription factors in the immune system. Annu Rev Immunol 2009; 27: 693-733.
9. Kawauchi K, Araki K, Tobiume K, Tanaka N: Loss of p53 enhances catalytic activity of IKKβ through O-linked β-N-acetyl glucosamine modification. Proc Natl Acad Sci USA 2009; 106: 3431-3436.
10. Medzhitov R: Origin and physiological roles of inflammation. Nature 2008; 454: 428-435.
11. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545.
12. Kuper H, Adami HO, Trichopoulos D: Infections as a major preventable cause of human cancer. J Intern Med 2000; 248: 171-183. (Pubitemid 33702479)
13. Greten FR, Eckmann L, Greten TF, et al.: IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-296. (Pubitemid 39061110)
14. Grivennikov S, Karin E, Terzic J, et al.: IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-113.
15. Lee H, Herrmann A, Deng JH, et al.: Persistently activated Stat3 maintains constitutive NF-κB activity in tumors. Cancer Cell 2009; 15: 283-293.
16. Kishimoto T: Interleukin-6: from basic science to medicine - 40 years in immunology. Annu Rev Immunol 2005; 23: 1-21. (Pubitemid 40563163)
17. Kim H, Baumann H: The carboxyl-terminal region of STAT3 controls gene induction by the mouse haptoglobin promoter. J Biol Chem 1997; 272: 14571-14579. (Pubitemid 27251717)
18. Kim JH, Bachmann RA, Chen J: Interleukin-6 and insulin resistance. Vitam Honn 2009; 80: 613-633.
19. Inoue H, Ogawa W, Ozaki M. et al.: Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 2004; 10: 168-174.
20. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000; 18: 621-663.
21. Kawauchi K, Araki K, Tobiume K, Tanaka N: Activated p53 induces NF-κB DNA binding but suppresses its transcriptional activation. Biochem Biophys Res Commun 2008; 372: 137-141.
22. Mathupala SP. Ko YH. Pedersen PL: Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006; 25: 4777-4786.
23. Yalcin A, Telang S, Clem B, Chesney J: Regulation of glucose metabolism by 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol 2009; 86: 174-179.
24. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE: Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009; 324: 1713-1716.
25. Bromberg JF, Wrzeszczynska MH, Devgan G, et al.: Stat3 as an oncogene. Cell 1999; 98: 295-303.
26. Haura EB, Turkson J, Jove R: Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005; 2: 315-324.
27. Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.